Revenue increased 9.0%
Revenue changed +9.0% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed +9.0% from the comparable as-filed period.
Research & development changed +82.3% from the comparable as-filed period.
Cash & equivalents changed +4.4% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Selling, general & administrative changed -2.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Inventory changed +1.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.